Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,611 across all filing types
Latest filing 2020-05-11 Fund Information / Fact…
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
109年4月營業收入
Fund Information / Factsheet Classification · 85% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 杏輝 for the period 民國109年04月 (April 2020). It contains numerical financial data comparing current and prior periods, with percentage changes and notes on accounting standards (IFRS). The document length is short (768 characters) and it appears to be a brief financial summary rather than a full financial report. It does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). It is also not an announcement or notice but a direct data report. Given the nature and brevity, this fits best as a Fund Information / Factsheet (FS) type, which is a brief summary of key company financials and market info.
2020-05-11 Chinese
109年4月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document contains financial data related to guarantees and endorsements, with monthly and cumulative amounts, but it is very short (615 characters) and does not contain comprehensive financial statements or detailed analysis. It appears to be a regulatory disclosure of financial guarantees rather than a full report. There is no indication of an annual or interim report, audit report, or other detailed filings. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2020-05-11 Chinese
本公司依公開發行公司資金貸與及背書保證處理準則 第二十五條第一項第四款規定公告
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from a publicly listed company (杏輝) regarding the provision of guarantees and endorsements for a subsidiary company. It details the amounts, conditions, and financial ratios related to the guarantees. The document is short (1163 characters) and is a formal disclosure of a financial guarantee event, not a financial report or earnings release. It does not contain financial statements or management discussion but is a compliance disclosure under specific regulatory rules. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-05-08 Chinese
109年04月僑外投資持股
Major Shareholding Notification Classification · 95% confidence The document is a statistical table showing the shareholding situation of overseas and mainland China investors, including changes before and after a shareholders' meeting date. It includes details such as stock codes, shareholding numbers, and regulatory approvals. The document length is short (1065 characters) and it primarily reports shareholding data related to a shareholders' meeting event. There is no indication of a full financial report, audit, or management discussion. It is not a voting result announcement but rather a notification of shareholding status changes due to a shareholders' meeting. This fits best with the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or related shareholding statistics.
2020-04-27 Chinese
109年03月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document contains detailed tabular data about shareholdings of company insiders, including directors, supervisors, general managers, and their family members. It lists the number of shares held, changes in holdings, and other related information. The content is focused on insider share transactions and holdings rather than financial results, management changes, or meeting materials. There is no indication of it being a full financial report, earnings release, or management discussion. The document is not a report publication announcement or a certification. Given the detailed insider shareholding data, this fits the definition of Director's Dealing (DIRS), which reports personal share transactions by company directors and executives (insider trades). The document length is sufficient and the content matches the insider dealing category clearly.
2020-04-13 Chinese
109年03月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders and related parties of the company 杏輝藥品工業股份有限公司, including directors, supervisors, and senior management. It lists the number of shares held, pledged shares, and related percentages. The document is 3285 characters long, which is relatively short and focused solely on insider shareholdings. There is no indication of financial statements, management discussion, earnings data, or meeting materials. The content matches the description of a Director's Dealing report, which reports personal share transactions or holdings by company directors and executives. Therefore, the document should be classified as a Director's Dealing (DIRS) filing.
2020-04-13 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.